> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eton Pharma NDA for Liquid Epilepsy Drug
- URL: https://www.fdaweb.com/eton-pharma-nda-for-liquid-epilepsy-drug/
- Published: 2020-07-30T12:00:00.000Z
- Updated: 2026-09-14T16:23:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147316

Eton Pharmaceuticals has submitted an NDA for zonisamide (previously known as ET-104) oral suspension for treating partial seizures in patients with epilepsy. Zonisamide is widely used as a capsule to treat partial seizures, but the molecule is not FDA-approved in a liquid form. Eton says its patent-pending liquid formulation addresses the significant unmet need for patients with dysphagia and patients that require the precision dosing that a liquid product offers. Based on recent data, more than 150,000 prescriptions of zonisamide are written annually for the indication. ET-104 is one of the company’s three neurology-focused liquid product candidates, along with ET-105 (lamotrigine oral suspension) and ET-101 (topiramate oral solution). Eton expects all three to be approved and launched in 2021.